Dutch Biotech Micreos #Alternative to Antibiotics# Wins Ideas From Europe Finals

Food and Healthcare Press Releases Friday April 27, 2018 10:04
THE HAGUE, Netherlands--27 Apr--PRNewswire/InfoQuest

In the iconic Hall of Knights, packed with public and policymakers, Dutch biotech Micreos 'sustainable alternative to antibiotics' was chosen as Europe's most relevant innovation, at the finals of the EU's Ideas from Europe competition. Ideas from Europe is a European initiative that facilitates sustainable innovations aimed at addressing global challenges.

(Photo: https://mma.prnewswire.com/media/682961/Ideas_from_Europe_Finalists.jpg )

In the presence of Mrs. Elsbieta Bienkowska, European Commissioner Internal Market, Industry, Entrepeneurship and SMEs, and Mrs. Mona Keijzer, State Secretary Economic Affairs & Climate Policy, 12 finalists pitched their inspiring innovations to tackle global challenges, such as healthcare challenges, climate change, immigration, bullying, food waste, extinction of species and renewable energy. Public and policymakers at the Knights Hall then chose their most impactful innovation.

With Micreos' endolysin technology, for the first time it is possible to kill only the unwanted bacteria, regardless of antibiotic resistance. Contrary to existing antibiotics it leaves the beneficial bacteria - essential for our health - intact, preserving the microbiome.

Micreos CEO Mark Offerhaus: "Antibiotic-resistance is an enormous global problem. We've already been able to help over 50.000 people suffering from inflammatory skin diseases such as eczema, acne and rosacea, and wound infections caused by the Staphylococcus aureus bacteria, including the resistant MRSA, but millions can and should benefit. Patients and policymakers need to take their responsibility. There is no need to wait and there is no time to lose."

Watch Finals pitch by Micreos CEO Mark Offerhaus: https://youtu.be/J2gGTZ6Fcrs
Ideas from Europe

Ideas from Europe is a European platform aimed at promoting the development of ideas for society's major challenges. The concept behind Ideas from Europe is that the involvement of the public at large can propel relevant breakthrough innovation ( http://www.ideasfrom.eu ).

About Micreos

Micreos ( http://www.micreos.com ) develops endolysin- and phage technology that enables targeted killing of only unwanted bacteria. The company is considered the leader in this exciting new field. Micreos runs its own production and R&D centre for endolysins in Bilthoven (Human Health) and for phages ( food safety) in Wageningen. The company works together with ETH Zurich and numerous medical and technology centres, including Erasmus MC (Rotterdam), Public Health Lab Kennemerland, the Dutch Burn Centres (Beverwijk) and many others. Gladskin is a Micreos Human Health brand ( http://www.gladskin.com ).

For further information: Dirk de Meester: +31-6-46048503 - d.demeester@micreos.com
Source: Micreos

Latest Press Release

Venus Medtech Launches Global Advisory Board to Target for International Market

Venus Medtech (Hangzhou) Inc., a Chinese medical device company specializing in transcatheter valve replacement therapy, has retained four world-renowned experts specialized in interventional cardiovascular to form a Global Advisory Board. The Board...

Future Health Index, Commissioned by Philips, Identifies Key Recommendations for Better Health Information Exchange to Drive Value in Healthcare

Royal Philips (NYSE: PHG) (AEX: PHIA), a global leader in health technology, today released a new Future Health Index (FHI) report " Moving data to the heart of health systems: Increasing vital technology adoption to make value-based healthcare a reality...

PULSUS Group collaborates with Anbu Kochi to Contribute towards Kerala Flood Victims

In a humanitarian effort, PULSUS Group - in collaboration with Anbu Kochi - is responding to the calamity of the recent, unprecedented floods in the Indian state of Kerala by providing contributions to aid relief and rehabilitation measures. PULSUS Group...

Menarini Ricerche Announces New Positive Results in Acute Myeloid Leukemia Cell Lines for MEN1112/OBT357 at the 60th Annual SIC Meeting

Menarini Ricerche will present tomorrow, September 20th, at the 60th Annual Meeting of the Italian Cancer Society (SIC), new preclinical data showing that pre-treatment with 5-Azacytidine and Decitabine enhances the Antibody-dependent cellular...

Experts Call for Improved Identification of #High Burden# Rosacea Patients in Everyday Practice

- Additional analysis of global survey data reveals quality of life is impacted by several factors extending beyond severity of rosacea alone Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report...

Related Topics